Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Rezolute, Inc. Market Cap
Based on ratings from 0 stock analysts, the Rezolute, Inc. stock price is expected to increase by 107.16% in 12 months. This is calculated by using the average 12-month stock price forecast for Rezolute, Inc.. The lowest target is $7 and the highest is $14. Please note analyst price targets are not guaranteed and could be missed completely.
Rezolute, Inc. has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that Rezolute, Inc. will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of RZLT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Debjit Chattopadhyay Guggenheim | Buy | $11 | Initiates | Aug 27, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $14 | Reiterates | Aug 6, 2024 |
| Jason McCarthy Maxim Group | Buy | $10 | Maintains | Aug 6, 2024 |
| Julian Harrison BTIG | Buy | $13 | Initiates | Jul 17, 2024 |
| Christian Schwab Craig-Hallum | Buy | $14 | Initiates | Jun 4, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $14 | Reiterates | May 22, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $14 | Reiterates | May 16, 2024 |
| Jason Butler JMP Securities | Market Outperform | $7 | Reiterates | Apr 19, 2024 |
| Jason Butler JMP Securities | Market Outperform | $7 | Reiterates | Apr 18, 2024 |
| Catherine Novack JonesTrading | Buy | $10 | Initiates | Apr 18, 2024 |
| Jason McCarthy Maxim Group | Buy | $8 | Initiates | Apr 9, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $14 | Reiterates | Mar 7, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $14 | Reiterates | Feb 14, 2024 |
| Jason Butler JMP Securities | Market Outperform | $7 | Maintains | Nov 14, 2023 |
| Pete Stavropoulos Cantor Fitzgerald | Overweight | $5 | Reiterates | Sep 19, 2023 |
| Douglas Tsao HC Wainwright & Co. | Buy | $14 | Reiterates | Sep 18, 2023 |
| Jason Butler JMP Securities | Market Outperform | $8 | Reiterates | Sep 15, 2023 |
| Douglas Tsao HC Wainwright & Co. | Buy | $14 | Reiterates | Jun 28, 2023 |
| Pete Stavropoulos Cantor Fitzgerald | Overweight | $5 | Maintains | Jun 28, 2023 |
| Edward Nash Canaccord Genuity | Buy | $17 | Maintains | May 19, 2023 |
When did it IPO
N/A
Staff Count
41
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Nevan Charles Elam J.D.
Market Cap
$265.2M
In 2023, RZLT generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that RZLT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
